SEC Form 4 · accession 0001209191-16-153644
CELGENE CORP /DE/ · CELG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael F. Pehl
Officer — See remarks
Period of report
Dec 2, 2016
Accepted (ET)
Dec 6, 2016 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816284
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 2, 2016 | M | 1,880 | $0.00 | A | 1,880 | D | |
| Common Stock | Dec 2, 2016 | F | 892 | $117.63 | D | 988 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF3,F1,F2 | — | Dec 2, 2016 | M | 1,880 | D | — | — | Common Stock | 1,880 | 0 | D |
Explanation of responses
- F1All of the restricted stock units granted to the reporting person on December 2, 2013 vested and settled for shares of the Company's common stock.
- F2Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
- F3The restricted stock units were issued pursuant to The Celgene Corporation 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015).
Remarks
President, Hematology & Oncology